JPWO2020120978A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020120978A5 JPWO2020120978A5 JP2021534203A JP2021534203A JPWO2020120978A5 JP WO2020120978 A5 JPWO2020120978 A5 JP WO2020120978A5 JP 2021534203 A JP2021534203 A JP 2021534203A JP 2021534203 A JP2021534203 A JP 2021534203A JP WO2020120978 A5 JPWO2020120978 A5 JP WO2020120978A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- referred
- peptide ligand
- cysteine residues
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 239000003446 ligand Substances 0.000 description 20
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 15
- 108050003558 Interleukin-17 Proteins 0.000 description 11
- 102000013691 Interleukin-17 Human genes 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 108010077895 Sarcosine Proteins 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 229940043230 sarcosine Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 description 1
- SXMHOCOUAHRQCW-UHFFFAOYSA-N 2-(3-methoxy-2-oxochromen-4-yl)acetic acid Chemical group C1=CC=C2OC(=O)C(OC)=C(CC(O)=O)C2=C1 SXMHOCOUAHRQCW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- 101000685323 Homo sapiens Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000046038 human SDHA Human genes 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002062 molecular scaffold Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1820316.6A GB201820316D0 (en) | 2018-12-13 | 2018-12-13 | Bicyclic peptide ligands specific for IL-17 |
| GB1820316.6 | 2018-12-13 | ||
| PCT/GB2019/053534 WO2020120978A1 (en) | 2018-12-13 | 2019-12-13 | Bicyclic peptide ligands specific for il-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022515720A JP2022515720A (ja) | 2022-02-22 |
| JPWO2020120978A5 true JPWO2020120978A5 (enrdf_load_stackoverflow) | 2022-12-19 |
Family
ID=65146974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534203A Pending JP2022515720A (ja) | 2018-12-13 | 2019-12-13 | Ｉｌ－１７に特異的な二環式ペプチドリガンド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220024983A1 (enrdf_load_stackoverflow) |
| EP (1) | EP3894007A1 (enrdf_load_stackoverflow) |
| JP (1) | JP2022515720A (enrdf_load_stackoverflow) |
| CN (1) | CN113474046A (enrdf_load_stackoverflow) |
| GB (1) | GB201820316D0 (enrdf_load_stackoverflow) |
| WO (1) | WO2020120978A1 (enrdf_load_stackoverflow) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019410261A1 (en) | 2018-12-19 | 2021-06-17 | Leo Pharma A/S | Amino-acid anilides as small molecule modulators of IL-17 |
| GB201918558D0 (en) * | 2019-12-16 | 2020-01-29 | Bicycle Tx Ltd | Bicyclic peptide ligands specific for IL-17 |
| EP4077349A1 (en) * | 2019-12-16 | 2022-10-26 | BicycleTX Limited | Bicyclic peptide ligands specific for il-17 |
| GB201918559D0 (en) * | 2019-12-16 | 2020-01-29 | Bicycle Tx Ltd | Bicyclic peptide ligands specific for IL-17 |
| GB201918557D0 (en) * | 2019-12-16 | 2020-01-29 | Bicycle Tx Ltd | Bicyclic peptide ligands specific for IL-17 |
| UY39188A (es) | 2020-04-30 | 2021-10-29 | Janssen Biotech Inc | Imidazopiridazinas como moduladores de il-17 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| NZ560504A (en) | 2005-01-24 | 2009-07-31 | Pepscan Systems Bv | Binding compounds, immunogenic compounds and peptidomimetics |
| AU2006325860B2 (en) | 2005-12-13 | 2011-09-22 | Eli Lilly And Company | Anti-IL-17 antibodies |
| DK2474613T3 (da) | 2008-02-05 | 2014-10-06 | Bicycle Therapeutics Ltd | Fremgangsmåder og sammensætninger |
| US20110223169A1 (en) | 2008-11-26 | 2011-09-15 | Stern Michael E | Il-17 antibody inhibitor for treating dry eye |
| EP2569335B1 (en) | 2010-05-14 | 2018-08-22 | Orega Biotech | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists |
| US20130195868A1 (en) | 2010-06-24 | 2013-08-01 | Eleven Biotherapeutics, Inc. | Treating surface of the eye disorders |
| CN107148425B (zh) * | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| EP3181146A1 (en) * | 2015-12-16 | 2017-06-21 | Ruprecht-Karls-Universität Heidelberg | Cyclic ntcp-targeting peptides and their uses as entry inhibitors |
| GB201600911D0 (en) * | 2016-01-18 | 2016-03-02 | Bicycle Therapeutics Ltd | Stabilized peptide derivatives |
| GB201810327D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to IL-17 |
-
2018
- 2018-12-13 GB GBGB1820316.6A patent/GB201820316D0/en not_active Ceased
-
2019
- 2019-12-13 WO PCT/GB2019/053534 patent/WO2020120978A1/en unknown
- 2019-12-13 JP JP2021534203A patent/JP2022515720A/ja active Pending
- 2019-12-13 US US17/309,627 patent/US20220024983A1/en not_active Abandoned
- 2019-12-13 EP EP19824377.6A patent/EP3894007A1/en not_active Withdrawn
- 2019-12-13 CN CN201980081501.8A patent/CN113474046A/zh active Pending